GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » PB Ratio

KTTA (Pasithea Therapeutics) PB Ratio : 0.16 (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-15), Pasithea Therapeutics's share price is $2.65. Pasithea Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $17.05. Hence, Pasithea Therapeutics's PB Ratio of today is 0.16.

The historical rank and industry rank for Pasithea Therapeutics's PB Ratio or its related term are showing as below:

KTTA' s PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.27   Max: 0.79
Current: 0.16

During the past 4 years, Pasithea Therapeutics's highest PB Ratio was 0.79. The lowest was 0.08. And the median was 0.27.

KTTA's PB Ratio is ranked better than
98.83% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs KTTA: 0.16

During the past 12 months, Pasithea Therapeutics's average Book Value Per Share Growth Rate was -37.40% per year.

Back to Basics: PB Ratio


Pasithea Therapeutics PB Ratio Historical Data

The historical data trend for Pasithea Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics PB Ratio Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- 0.79 0.39 0.33

Pasithea Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.33 0.38 0.33 0.32

Competitive Comparison of Pasithea Therapeutics's PB Ratio

For the Biotechnology subindustry, Pasithea Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pasithea Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's PB Ratio falls into.



Pasithea Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Pasithea Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=2.65/17.047
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Pasithea Therapeutics  (NAS:KTTA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Pasithea Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pasithea Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Executives
Graeme Martin Currie officer: Chief Development Officer 51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a 10 percent owner C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd. other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian other: Member of 10% owner group 350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp other: Member of 10% owner group CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc other: Member of 10% owner group 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977

Pasithea Therapeutics Headlines

From GuruFocus